[Alendronate-induced severe esophagitis. A rare and severe reversible side-effect illustrated by three case reports].
The bisphosphonate, alendronate sodium (e.g. Fosamax), a bone resorption inhibitor used to treat osteoporosis, has occasionally been reported to cause severe oesophagitis. The characteristic endoscopy findings include oesophageal ulceration with discoloured exudate, a narrowed lumen and denuded, haemorrhagic mucosa. The oesophagitis heals on discontinuation of alendronate medication, and the institution of gastric acid suppression treatment. The article consists in discussion of such adverse reactions, illustrated by three case reports. As many of the patients selected for alendronate treatment are elderly and handicapped, to minimise the risk of serious side-effects it is important not only to give detailed instructions regarding medication, but also to ensure that they are properly understood. As a history of swallowing problems was a feature of all three cases reported, caution is recommended before treating such patients with alendronate sodium.
Tóth
E
E
Röntgendiagnostiska avdelningen, Universitetssjukhuset MAS.
Fork
F T
FT
Lindelöw
K
K
Lindström
E
E
Verbaan
H
H
Veress
B
B
D000368:Aged; D019386:Alendronate / Q000009:adverse effects*; D002057:Burns, Chemical / Q000209:etiology / Q000473:pathology; D004164:Diphosphonates / Q000009:adverse effects*; D004940:Esophageal Stenosis / Q000139:chemically induced / Q000473:pathology; D004941:Esophagitis / Q000139:chemically induced* / Q000473:pathology; D004945:Esophagoscopy; D004947:Esophagus / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy
D004164:Diphosphonates; D019386:Alendronate